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I. INTRODUCTION 
The Visual Impairment/Intracranial Pressure (VIIP) Research and Clinical Advisory Panel 
convened on December 1, 2014 at the ISS Conference Facility in Houston. The panel members 
were provided updates to the current clinical cases and treatment plans along with the latest 
research activities (http://humanresearchroadmap.nasa.gov/Risks/?i=105) and preliminary study 
results. The following is a summary of this meeting. 
 
II. ATTENDEES 
RCAP Members  
1. David Baskin, M.D. - Methodist Hospital; Houston, TX 
2. Conrad Johanson, Ph.D. - Brown Medical School; Providence, Rhode Island 
3. Byron Lam, M.D. – Bascom Palmer Eye Institute; Miami, Florida 
4. Andrew Lee, M.D. - Methodist Hospital; Houston, TX  
5. J.D. Polk, D.O., M.S., M.M.M., C.P.E. - College of Osteopathic Medicine, Des Moines 
University; Des Moines, Iowa 
6. Harold Rekate, M.D. - North Shore Long Island Jewish Health System; Great Neck, NY 
7. Prem Subramanian, M.D., Ph.D. - Wilmer Eye Institute, Johns Hopkins University School 
of Medicine; Baltimore, MD 
 
Participants 
1. Patricia Bahr 
2. Yael Barr 
3. Michael Barratt 
4. David Baumann 
5. Eric Bershad 
6. Rachel Brady 
7. Jon Clark 
8. Ronita Cromwell 
9. Jeffrey Davis 
10. Dorit Donoviel 
11. Doug Ebert 
12. Millennia Foy 
13. David Francisco  
14. Charles (Bob) Gibson 
15. Steve Hart 
16. Janet Kavandi 
17. Steven Laurie 
18. Justin Lawley 
19. Tom Mader 
20. Sara Mason 
21. Shannan Moynihan 
22. Lealem Mulugeta 
23. Peter Norsk 
24. Christian Otto 
25. Nimesh Patel 
26. Ashot Sargsyan 
27. Mark Shelhamer 
28. Michael Stenger 
29. Bradley Rhodes 
30. Graham Scott 
31. Scott Smith 
32. Jeffrey Sutton 
33. Terrance Taddeo 
34. William Tarver 
35. Wafa Tayim 
36. Mary Van Baalen 
37. Jennifer Villarreal  
38. Sharmi Watkins 
39. Mary Wear 
40. Jimmy Wu 
 
 
Commented [V1]: Consider adding the statement of risk and 
links to HRR.  
3 
 
III. MEETING AGENDA 
 
Time Topic Presenter(s) 
8:30 Welcome and Introductions 
Dr. Jeff Davis 
Jennifer Villarreal 
8:45 Latest case review Thomas Mader 
9:15 Ocular Health flight study preliminary data Christian Otto 
9:45 New clinical practice guideline overview Shannan Moynihan 
10:15 Break  
10:45 Changes to Medical Requirements (MRID) testing Steve Hart 
11:15 Pre/post flight lumbar puncture MRID Bill Tarver 
11:45 Lunch  
12:00 Lunch Speaker: Invasive Telemetric ICP Monitoring Christian Otto 
12:30 Clinical treatment/data review Shannan Moynihan
1:00 Russian implementation and data comparability Jimmy Wu 
1:30 1-Carbon study results Scott Smith 
2:00 Microgravity ICP on Zero-G plane Justin Lawley 
2:30 Cardiac profile data  Christian Otto 
3:00 Break  
3:15 Retrospective OCT analysis Nimesh Patel 
3:45 Discussion and recommendations All 
5:00 Action Summary & Adjourn Jennifer Villarreal 
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IV. KEY DISCUSSION POINTS 
The following topics were presented to and discussed by the panel.  The comments and 
recommendations summarized below do not necessarily represent the unanimous opinion of the panel.     
OCT related comments/recommendations 
 
 OCT analysis was presented and discussed. A potential relationship between the size of the 
Bruch’s Membrane Opening (BMO) area and RNFL thickening was noted, such that larger optic 
nerves have bigger RNFL changes.  
 
 Evaluate anterior segment via Optical Coherence Tomography (OCT).  The volume of the choroid 
increases inflight, without a concomitant increase in IOP. This means that another volume within 
the eye is decreasing, possibly that of the anterior chamber, due to a decrease in aqueous humor 
production. However, a decrease in anterior chamber volume would move the lens forward and 
increase myopia, which has not been seen in crewmembers.  This can be evaluated with the 
addition of anterior segment OCT.  Note: NASA’s “Fluid Shifts” flight research study includes 
measurement of this parameter. 
 
 Consider OCT angiogram/venogram software to measure venous engorgement/venous outflow.  
Optic nerve sheath (ONS) distention places anterior pressure on the globe, causing choroidal folds, 
but the choroidal folds could be secondary to choroidal congestion.  
 
 Consider evaluating space-naïve, high performance pilots, with OCT and other technologies, to 
obtain measurements of the choroid, RNFL, peripapillary total retinal volume, ONSD, etc. 
 
 Consider getting corneal topography on crewmembers pre-, in- and postflight.  Note: Currently we 
collect keratometry data using the IOL Master, not corneal topography.  
 Consider looking at the ganglion cell layer at the macula/fovea, as well as measuring the choroidal 
thickness at the macula. At present we have limited macular data.  Most OCT data is peri-macular.  
 
 Use OCT preflight to look at the lamina cribrosa position and structure as well as peripapillary total 
retinal volume. 
 
 Look at OCT-MRW post fenestration of IAH-ICP patients to inform us whether fenestration is a 
viable therapy in the future for Mars missions, etc. 
 
 Get OCT on Skylab and Shuttle-Mir astronauts to evaluate for permanent structural changes (striae, 
scarring) for evidence of the VIIP syndrome.  
 
 Considerable progress has been made on understanding the nature of the retinal fiber layer damage 
in long duration flights.. The high tech OCT on orbit has proven valuable for delineating the fine 
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structural damage in the back of the eye and optic nerve head. This should help to devise treatment 
strategies for pin-pointing targets to pharmacologically minimize pathology and loss of visual 
functions.  
 
Ultrasound and MRI related comments/recommendations 
 
 Evaluate venous outflow, the subarachnoid fluid around the sheath, and the distribution of the CSF 
by quantitative MRI. In Alperin’s IIH MRI study he found an increase in the volume of 
extraventricular intracranial CSF volume in IIH patients.  Note: An existing NASA grant includes 
these parameters.  Results should be available by the next RCAP meeting. 
 
 Consider in-flight imaging of transverse sinus morphology.  In non-obese IIH patients, changes in 
the transverse sinus geometry are common and they reverse when pressure is lowered with an LP.  
Note: Ultrasound (U/S) imaging is limited to the deep vein of Rosenthal.  
 
 Consider evaluation of eye morphology/geometry.  It is unknown if the globe shortening is due to 
the eye getting smaller, or if concurrently the geometry of the eye is changing so that the height 
increases to compensate for the axial shortening. We only measure axial length (Anterior-posterior 
diameter), not globe height. Notes: There is an MRI technique that can evaluate 3D globe 
morphology. A 3D volumetric ultrasound is in development by Dr. Dentinger in collaboration with 
General Electric under an NSBRI funded grant. Reference  
http://www.nsbri.org/projects/indivProject.asp?id=440&projID=311 
 
 Investigate the nature of optic nerve sheath diameter change - permanence, elasticity, ultrastructure. 
 
 Sequestration of CSF in the optic nerve sheath - Measure the anatomical structure of the optic 
nerve sheath complex on the preflight MRI. 
 
 Consider evaluation of eye vessel diameters – At present the resolution of U/S only allows 
visualization of flow velocity but cannot visualize the vessel itself. However, it is the actual vessel 
diameters that are important. The RCAP members noted that flow velocity is not used clinically 
because it is only a surrogate to flow, which is a surrogate to diameter.  
 
 Mathematical models are needed to evaluate the correlations between findings, to determine which 
measurements and tests best predict outcome measures, and to prioritize which clinical/research 
tests are of most value. Note: Modeling is underway in NASA’s Digital Astronaut project and 
external collaborations funded by NSBRI.  Reference 
http://humanresearchroadmap.nasa.gov/Gaps/?i=576 and 
http://www.nsbri.org/projects/indivProject.asp?id=358&projID=327 .  
 
 The MRI technique to calculate CSF production rate is flawed and prone to error because the total 
volume of each pulse is so much higher than the net flow. Two RCAP members noted that CSF 
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formation rate does not change over a large range of ICP values. Formation rate could change with 
a medication such as Diamox, but not secondary to increased or decreased pressure. In addition, as 
long as the CSF absorption is the same, an increase in CSF production postflight will not increase 
ICP. Another RCAP member noted that there is anatomical evidence from rats that supports 
decreased CSF formation in-flight and increased CSF formation postflight. The hypothesized 
mechanism: Increased ICP decreases the perfusion pressure in the choroid plexus capillaries, 
leading to less blood flow, less filtration, and less CSF production. Also could be secondary to 
changing levels of ANP or its receptors. 
 
 Consider characterizing the structural or secondary complications of the increased volume in the 
choroid using a 7.1 Tesla MRI. Consider pre/postflight 7.1 Tesla MRI of the eye and ONSD with 
eye coils. 
 
 Consider using a 7.1 Tesla MRI to evaluate the arachnoid villi for damage that may be secondary 
to increased venous pressure and loss of venous hydrostatic gradient. 
 
 In MRI analyses by Dr. Donna Roberts (NASA grant), blood-brain permeability to gadolinium 
could be assessed to explore the status of the brain capillaries in spaceflight. 
 
 The ability of MRI to measure compliance is an important step forward. Recommend extensively 
pursuing these compliance measurements in astronauts via MRI. 
 
 
Treatment comments/recommendations 
 
 Consider being more aggressive with in-flight treatment of cases. The RCAP’s assumption until 
now was that in the mild cases we can just watch and see, but we now see a case that was mild in-
flight and yet postflight they are not improving or even worsening, so perhaps earlier intervention 
is warranted.  
 
 Several panelists agreed that the treatment protocol should follow visual fields and not visual 
acuity, as the visual acuity changes are refractive in nature, and terrestrial standard of care is to 
monitor with visual fields. Several felt that visual acuity should not be used for high stakes 
decisions like “de-orbit” because of low sensitivity and low specificity (e.g. loss of acuity might be 
refractive shift and normal acuity can occur in papilledema with severe visual loss).  
 
 Develop visual field technology for mission use. 
 
 Treatment with Diamox in-flight might make the translaminar pressure worse by decreasing the 
IOP. If IOP is slightly increased in-flight that may be protective against worse disc edema. 
Lowering IOP is almost certainly a bad idea. Consider an in-flight study with Diamox 
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administration (2 grams daily, for 3 days) to evaluate what happened to IOP and OCT parameters. 
Give for 72 hours in-flight. While this is a large dose, it will be given for a short period of time. 
 
 Consider preflight optic nerve fenestration as a preventative measure prior to an extra-long 
duration mission (such as a 1-year mission to the ISS or a longer mission to Mars). The RCAP 
members had differing opinions on this, with some quoting a high early failure rate and a very high 
complication rate, and making the point that since we don’t understand the etiology of VIIP, it is 
premature to attempt preventive measures that are so invasive and high-risk.  
 
 Identify prophylactic agents to minimize damage to ganglion cells/ RNFL in spaceflight. 
 
 Consider potential pharmacologic agents to unload central venous volume (pressure) increased by 
microgravity. Strategies to reduce augmented central venous volume in spaceflight may be 
important in attaining greater effectiveness of CSF formation-inhibiting (or CSF reabsorption-
enhancing) agents. To lower ICP, the use of more than one pharmacologic agent (or therapeutic 
modality) may be necessary to mobilize CSF, brain interstitial fluid, and central venous blood that 
are not being efficiently cleared from the intracranial and extracranial spaces. 
 
 Evaluate agents to reduce formation of CSF, and whether there are agents better than 
acetazolamide (Diamox) to control ICP. 
 
ICP measurement comments/recommendations  
 
 Most panelists agreed that ICP data is needed urgently. At least one expressed that it is unethical to 
send people on longer missions without understanding the risk to their health. This may be 
accomplished with a pre and postflight LP combined on all crewmembers with noninvasive 
pre/post measurement and noninvasive in-flight, or with implanted ICP probes (3-4 crewmembers 
would be sufficient to establish proof of concept). Ideally, LP would be done on all crewmembers 
pre- and postflight. LP can be done 6-12 months preflight, but postflight needs to occur as soon as 
possible after landing, preferably on the first day back on Earth.  
 
 Lumbar CSF composition can yield considerable information about the state of the choroid plexus 
(an influential player in CSF dynamics) as well as brain metabolism and viability. As the 
biomedical literature continually provides new insights on CSF neurochemistry, it is prudent to add 
analytes to astronaut CSF samples. Dr. Harold Rekate is able to analyze CSF samples for multiple 
novel biomarkers (6 cc of CSF will allow a full battery, although 1 cc can be sufficient for multiple 
tests, because of microliter analysis methods). Do both proteomics and metabolomics – look wide 
and then narrow the list. Add a test for level of melatonin in the CSF.  
 
 Consider analyzing frozen CSF samples previously collected from crewmembers for these 
biomarkers. However, the samples may not have been frozen in a way that is conducive to such 
analysis (i.e. potentially not snap frozen in liquid nitrogen). Future samples should be frozen 
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immediately in liquid nitrogen. Dr. Rekate will send Dr. Tarver the recommended freezing protocol 
for CSF. 
 
 Assess aquaporin 1 and 4 levels in CSF, pre-(control) and postflight, as a gauge of possible choroid 
plexus injury. AQP1 resides in the apical (CSF-facing) membrane of choroid plexus. Damage to 
the plexus (from radiation, gross ventricular fluid shifts in rats in Shuttle flights, etc.) might elevate 
AQP1 in CSF. AQP1 is uniquely a marker for choroid plexus, since it is not normally expressed in 
any other region in the CNS. By analogy, any AQP4 found in CSF would likely reflect 
pathophysiology to the ventricular wall, as is the case when AQP4-containing ependymal cells are 
damaged (stripped) in hydrocephalus. Maintaining the structural integrity of the CSF-bordering 
plexus and ependyma is essential for balancing fluid movements, and pressure gradients, between 
ventricles and brain. 
 
 Measure retinol (elevated 10-fold in terrestrial IIH) in astronauts to ascertain possible similar 
disruptions in the linkage of retinoid metabolism to CSF dynamics at arachnoidal drainage sites.  
Carrier RNP, and retinol, the substrate it binds, are normally present at certain levels and ratios, 
both in serum and CSF. Disturbances in vitamin A (retinoid) metabolism in some IIH patients 
causes a stoichiometric imbalance in RNP to retinol, i.e. possibly reflecting disorders in CSF 
reabsorption across the arachnoid membrane. 
 
 Six of eight panelists recommended implantable telemetric ICP probes for obtaining continuous 
ICP measurement in crewmembers. One expert panel member states that the risk of implanting the 
Raumedic device in normal subjects is very low and the risk of things like seizures or intracranial bleeding is 
very low (0.5% in skilled hands).   The risk noted in the literature (of hydrocephalic and very ill 
patients) is about 1 in 85 – quite significant but most likely not what we would see in healthy 
astronauts. The seizure rate noted for the hydrocephalic patients could be that high in this group of 
patients, even without probe implantation. Most RCAP members felt that the risk for peri-probe 
edema would not be higher due to spaceflight/fluid shifts.  The probe would be implanted months 
before the mission, and any edema would resolve within weeks. RCAP members noted that if such 
probes will be used on crew, it would help advance care for thousands of patients in the U.S. since 
there is not sufficient impetus to conduct studies and get this FDA approved.  However, from the 
practical perspective of flight operations, if the implanted crewmember complains of headache or 
fever onboard, NASA flight surgeons would have no choice but to deorbit, due to lack of on-board 
resources to rule out complication from the implant. That risk to the mission, and consequently 
NASA’s space program, may not be acceptable. However, RCAP members noted that the flight 
will occur several months after implantation, when a complication is very unlikely. The ethics of 
placing an invasive probe in a healthy person’s brain were also discussed. One RCAP member felt 
that the risk to the astronauts, mission and space program outweighs the need to know.  
  
 Using a transducer in the subdural intracranial of lumbar space was discussed. While a lumbar 
transducer would be safer, the results would be hard to interpret. The telemetric probe is not 
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compatible with lumbar insertion, because it is stiff, would touch nerves and be painful. The 
smaller flexible probes that could be used are not telemetric, which would limit their utility 
(extension through the skin increases infection risk, so these can be used only for a short period of 
time). A subdural probe usually ends up in the brain. Placing a probe in the cisterna magna is 
riskier than placing an intraparenchymal probe.  
 
 Consider flying to space an animal model (such as a primate) instrumented with the telemetric 
probe, or an instrumented patient on a “Make a Wish” type mission (as a tourist). 
 
 
Epidemiology, etiological hypotheses, and risk factor comments/recommendations 
 
 There were differing opinions among the RCAP members as to the etiological mechanisms 
underlying VIIP, with some supporting increased ICP as the leading mechanism and others 
supporting an eye/orbit/optic nerve centered mechanism (such as optic nerve compartment 
syndrome) with normal or slightly elevated ICP. It was recognized that the different theories are 
not mutually exclusive, and that the etiology might be multifactorial.  
 
 Data from Russian cosmonauts and USOS astronauts can be analyzed both separately or combined, 
while adjusting for gender, age, lifestyle, and other parameters. 
 
 Hyperhomocysteinemia is a known risk factor in men with terrestrial IIH. The thought is that these 
patients have a low level of thrombophilia, leading to partial venous outflow obstruction (look for 
papers by Gluck et al). The homocysteine levels in that IIH population are slightly higher than in 
the astronaut population (about 16 mmol). There is a different distribution of these genes in 
Russians, so would be interesting to evaluate in the cosmonauts. This could explain the cotton wool 
spots, and could also explain the gender difference in VIP incidence (as these polymorphisms tend 
to occur in males).  
 
The role of 1-C polymorphisms needs expansion and the mechanism of the pathophysiology needs 
to be identified.  It was also suggested that 1-C polymorphisms, blood levels of homocysteine, and 
their correlation to ICP and papilledema be evaluated in IIH patients.  
 
 Treating with folate or other vitamins (B6 and B12), while it brings the homocysteine levels down, 
does not reduce the risk of thrombophilia. However, since such treatment is low risk, it may be an 
option to try in affected crewmembers.  
 
 Patients with strokes also have a higher likelihood of high homocysteine and the question whether 
crew MRIs show any small vessel disease was discussed. While anecdotally some crewmembers 
have had punctate findings on MRI, no significant, or VIIP relationship has been noted to date. A 
re-evaluation of these MRIs was suggested. 
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 An RCAP member also suggested measuring 1-C metabolites (homocysteine, cystathionine and 
2MCA) in CSF of astronauts with polymorphisms vs. controls. These metabolites might be 
especially toxic to the retina and optic nerve if allowed to build up in blind cul-de-sacs of CSF. In 
addition, it was suggested that CSF samples from the subarachnoid space around the optic nerve 
might be collected and analyzed from IIH patients with and without the 1-C polymorphisms while 
they undergo optic nerve fenestration analyzed in IIH patients. 
  
 A recent zero-G study showed a decrease of ICP compared with supine measurements on the 
ground. Bed rest studies from the same group showed an increase in ICP with a return to supine 
levels after 3-24 hours of 6 degrees head-down tilt, with no elevation of ICP with 5 minutes of 
0.7% CO2 exposure. It was noted that it may take higher levels of CO2 to cause a significant 
increase to ICP – it is not a linear relationship. CO2 levels on ISS are 10X terrestrial levels. 
Expired CO2 levels were found to be 39.0 mmHg in 10 subjects, vs 36.7 mmHg preflight in the 
standing position (p<0.05). RCAP members questioned whether the patient population used 
(Ommaya reservoir patients) should be considered as having a “normal” central nervous system. 
The brief nature of the microgravity exposure on the parabolic plane was a concern to the RCAP 
members. However, other parameters (such as CVP) measured in the past during parabolic flights 
were later corroborated when measured during spaceflight. Unloading of the thorax during 
microgravity was speculated to underlie the decrease in absolute CVP and ICP in comparison to 
their supine ground level. This is in contrast to the 24 hour mean microgravity CVP and ICP which 
appear to be elevated above the mean 24 hour ground levels. 
 
 Segregate the data for those who are repeat fliers vs. those who were spaceflight naïve. 
Crewmembers who fly more than once could be considered in a separate category, because they 
may be predisposed to VIIP. 
 
 Consider methods to measure orbital compartment pressure.  In terrestrial IIH, within 2-3 weeks of 
lowering the ICP the disc edema resolves. However, in crewmembers the disc edema persists 
beyond normalization of the ICP, which supports that there could be scarring/structural changes to 
the eye, or continued localized pressure in the optic nerve sheath or the orbit.  
 
 Analyze systematically changes in CSF, brain and venous compliance; and ascertain factors 
affecting the compliance parameter in astronauts (state of fitness, anatomical variations, genetic 
predispositions, etc.)  Changing values of tissue, vascular and CSF compliance in microgravity are 
properties that deserve more attention in explaining the pathophysiology of intracranial fluid 
imbalance in spaceflight. Look at scleral compliance (biometrics) as well. 
 
 Continue CO2 studies. Consider studies that experimentally alter CO2 during spaceflight with a 
breathing device. 
 
 Consider the role of radiation and difference in high LET (linear energy transfer) with VIIP. 
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 An RCAP member questioned the value of bedrest studies to reproduce any of the changes seen 
with VIIP and suggested that inversion studies, even short-term, will give us a better idea of the 
shifts in fluids as well as forces being exerted in the microgravity environment. Combining 
exposures in the experimental models (CO2 + positioning; exercise + CO2 + inversion) may at first 
glance introduce too many variables, but it could have the best chance in the short term for 
identifying countermeasures. 
 
 Any VIIP-related testing postflight needs to occur as close to landing as possible (i.e. within a few 
to several days). Although done as quickly as practically possible, this is somewhat problematic in 
that homeostatic adjustments (microgravity back to 1G) in ICP and CSF formation can occur 
rapidly (neuroendocrine adaptations, e.g. ANP, within hours to a few days).  
 
 Consider the effects of re-entry deceleration on the pathophysiological status early postflight. 
Adding another layer of complexity to the assessment of pathophysiology and homeostatic rebound 
(or not) are the physical stressors, on fluid redistribution and pressure, caused by the reentry 
deceleration involving several G forces. It is possible that some of the physiological damage 
(possibly displaying hysteresis), on the delicate microarchitecture of the trabeculae in the 
subarachnoid space, occurs mainly in the stressful deceleration when returning to earth. 
 
 
V. CONCLUSION 
NASA extends its sincere appreciation to the distinguished panel members who have dedicated many 
hours of intellectual research and debate to assist NASA with this critical risk.  NASA will deliberately 
consider the advice of our esteemed panel members and implement the recommendations where 
possible and practical.  We also thank the extended team of scientists, physicians, and engineers who 
have made great strides towards elucidating the etiology behind the VIIP syndrome and potential 
mitigating countermeasures. 
 
